Antidepressant Potential of Ferula gummosa Essential Oil in Mouse Models

Document Type : Short communication


1 Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.

2 Department of Pharmacology and Toxicology, School of Pharmacy, Kermanshah University of Medical Science, Kermanshah, Iran.

3 Department of Basic Medical Sciences, Khoy University of Medical Sciences, Khoy, Iran.

4 Department of Public Health, School of Public Health, Khoy University of Medical Sciences, Khoy, Iran.

5 Department of Basic Medical Sciences, Khoy University of Medical Sciences, Khoy, Iran


Background and objectives: Earlier researches have exhibited the antioxidant, antinociceptive, and antiepileptic effects of Ferula gummosa. Considering that antioxidants play a key role in the pathogenesis of depression, the antidepressant potential of the F. gummosa essential oil was assessed by using a mouse models. Methods:Lorke’s method was used to access the acute toxicity of the F. gummosa essential oil. The F. gummosa essential oil (5-40 mg/kg), standard agents, and vehicle were administered to animals. The forced-swimming test (FST), tail suspension test (TST), and open-field test (OFT) were used for the evaluation of depression. Results: The F. gummosa essential oil LD50 was found to be 316.22 mg/Kg b.w. β-Pinene, α-pinene, guaiol, δ-3-carene, bulnesol, α-Bisabolol, and β-myrcenewere the major components of the F. gummosaessential oil, respectively. In both FST and TST, 10-40 mg/kg of the essential oil decreased the duration of immobility. Furthermore, 10-40mg/kg of the F. gummosa essential oil enhanced the duration of swimming with no significant effect on the duration of climbing in FST. The F. gummosaessential oil did not change the animal locomotion in the OFT. Conclusion: According to the results, the F. gummosa essential oil showed antidepressant activity similar to fluoxetine which may have a potential clinical value for the treatment of depression.


Main Subjects

  • Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, Mohr DC, Schatzberg AF. Major depressive disorder. Nat Rev Dis Primers. 2016; Article ID 16065.
  • Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiat. 2017; 4(5): 409–418.
  • Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012; 6: 369–388.
  • Santarsieri D, Schwartz TL. Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs Context. 2015; Article ID 212290.
  • Haller H, Anheyer D, Cramer H, Dobos G. Complementary therapies for clinical depression: an overview of systematic reviews. BMJ Open. 2019; 9(8):1–15.
  • Mahboubi M. Ferula gummosa, a traditional medicine with novel applications. J Diet Suppl. 2016; 13(6): 700–718.
  • Sayyah M, Kamalinejad M, Bahrami Hidage R, Rustaiyan A. Antiepileptic potential and composition of the fruit essential oil of Ferula gummosa Iran Biomed J. 2001; 5(2): 69–72.
  • Hassanzadeh SA, Abbasi Maleki S, Mousavi Z. Anti-depressive-like effect of monoterpene trans-anethole via monoaminergic pathways. Saudi J Biol Sci. 2022; 29(5): 3255–3261.
  • Guzmán Gutiérrez SL, Bonilla Jaime H, Gómez Cansino R, Reyes Chilpa R. Linalool and β-pinene exert their antidepressant-like activity through the monoaminergic pathway. Life Sci. 2015; 128: 24–29.
  • Ebrahimzadeh M, Nabavi S, Nabavi S, Dehpour A. Antioxidant activity of hydroalcholic extract of Ferula gummosa roots. Eur Rev Med Pharmacol Sci. 2011; 15(6): 658–664.
  • Mandegary A, Sayyah M, Heidari MR. Antinociceptive and anti-inflammatory activity of the seed and root extracts of Ferula gummosa in mice and rats. Daru. 2004; 12(2): 58–62.
  • Lorke D. A new approach to practical acute toxicity testing. Arc Toxicol. 1983; 54(4): 275–
  • Brown RE, Corey SC, Moore AK. Differences in measures of exploration and fearin MHC-congenic C57BL/6J and B6-H-2K mice. Behav Genet. 1999; 29: 263–271.
  • Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977; 229(2): 327–336.
  • Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacol. 1985; 85(3): 367–370.
  • Farokhmehr G, Najafi G, Abbasi Maleki S. Evaluation of the effect of Ferula gummosa essential oil on morphine tolerance and dependence in male mice. J Birjand Univ Med Sci. 2023; 29(4): 320–329.
  • Bogdanova OV, Kanekar S, D'Anci KE, Renshaw PF. Factors influencing behavior in the forced swim test. Physiol Behav. 2013; 118: 227–239.
  • Sadraei H, Asghari GR, Hajhashemi V, Kolagar A, Ebrahimi M. Spasmolytic activity of essential oil and various extracts of Ferula gummosa on ileum contractions. Phytomedicine. 2001; 8(5): 370–376.
  • Baek SE, Lee GJ, Rhee CK, Rho DY, Kim DH, Huh S, Lee SK. Decreased total antioxidant activity in major depressive disorder patients non-responsive to antidepressant treatment. Psychiatry Investig. 2016; 13(2): 222–226.
  • Muraro C, Dalla Tiezza M, Pavan C, Ribaudo G, Zagotto G, Orian L. Major depressive disorder and oxidative stress: in silico investigation of fluoxetine activity against ROS. Appl Sci. 2019; Article ID 3631.
  • Dadkhah A, Khalaj G, Fatemi F, Dini S, Hesaraki S, Naij S, Babaei M, Attaran HR. Evaluation the role of Ferula gummosa essential oil against the hepatoxicity induced by acetaminophen in animal model. J Med Plants. 2016; 15(60): 14–23.